The microglia hypothesis

Modulo Bio is built on the premise that the path to treating neurodegenerative disease lies in the brain's immune system. Specifically, the company focuses on microglia. These cells are the resident immune system of the central nervous system, responsible for maintaining neurons, repairing damage, and eliminating waste. In a healthy brain, microglia are neuroprotective. In a diseased brain, they can become toxic or simply fail to act.

Traditional drug discovery for conditions like Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s often targets the neurons themselves. Modulo takes a different approach by attempting to 'reprogram' the microglia to resume their protective roles. The company uses stem cell engineering to create human microglia-centered neuroimmune environments. This allows them to observe how these cells interact with neurons and astrocytes in a controlled, measurable setting that closely resembles human biology.

The engineering of biology

Based in San Diego, Modulo was founded by a team that blends high-level academic research with commercial engineering experience. CEO Mike Horowitz and CTO Scott Patterson lead the company; Patterson was previously the Vice President of Engineering at Counsyl, a genetics testing company acquired by Myriad Genetics. This technical pedigree is reflected in the company's hybrid approach, which treats biology as a data problem.

Their platform integrates multiomics, CRISPR, and single-cell techniques to manipulate cell models and analyze patient samples. The goal is to separate actual biological signal from the inherent 'noise' of laboratory models. The company’s name is a reference to the mathematical modulo operation, where different inputs can yield the same remainder. Modulo Bio applies this logic to neurobiology, searching for common therapeutic signals that persist across disparate disease models.

Machine learning for cell states

The central technical challenge Modulo addresses is the complexity of microglial behavior. These cells do not exist in binary states; they exhibit a wide variety of behaviors depending on their environment. Modulo uses machine learning to identify 'cell fingerprints' and functional biomarkers that correlate with health. By training models on high-dimensional data from their engineered microenvironments, they can predict which chemical compounds will shift microglia from a toxic state back to a beneficial one.

This platform-centric model is designed to scale across multiple indications. While the company emerged from stealth in 2023 with an initial focus on ALS and Frontotemporal Dementia (FTD), the underlying technology is applicable to any condition where the neuroimmune system plays a role, including Parkinson’s and Alzheimer’s. The company is backed by a range of investors, including Initialized Capital and specialized groups like the Alzheimer’s Drug Discovery Foundation and the ALS Association. This combination of venture capital and disease-specific non-profits suggests a strategy that values both technical scaling and clinical validation.